Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com

Omeros (NASDAQ:OMER) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Other analysts have also recently issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, February 20th. One analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Shares of OMER opened at $9.10 on Friday. The stock has a market capitalization of $527.35 million, a PE ratio of -3.94 and a beta of 2.03. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The company’s 50-day simple moving average is $8.70 and its 200-day simple moving average is $7.34.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in the company. Two Sigma Investments LP increased its stake in shares of Omeros by 8.8% during the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after buying an additional 13,201 shares during the period. ProShare Advisors LLC increased its stake in Omeros by 75.0% in the fourth quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 7,927 shares during the last quarter. Nomura Holdings Inc. increased its stake in Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the last quarter. Millennium Management LLC increased its stake in Omeros by 46.2% in the fourth quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock valued at $846,000 after purchasing an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Omeros by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 1,110 shares during the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.